EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell “missing self” recognition

Karl-Johan Malmberg, Ebba Sohlberg, Jodie P Goodridge, Hans-Gustaf Ljunggren

Immunogenetics · 2017-08 · 69 (8-9) · 547-556

DOI: 10.1007/s00251-017-1011-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunogenetics, online erschienen am 11.07.2017. Verfasst von Karl-Johan Malmberg und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. k.j.malmberg@medisin.uio.no. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Kreftforeningen, Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CTLA-4 AntigenHistocompatibility Antigens Class IHumansKiller Cells, NaturalNeoplasmsProgrammed Cell Death 1 ReceptorReceptors, KIRT-Lymphocytes, Cytotoxic

Stichwörter der Autor:innen

DifferentiationEducationHLAImmune escapeKiller cell immunoglobulin-like receptors (KIR)LeukemiaMHC class IMissing selfNatural killer (NK) cellTumor

Substanzen

CTLA-4 AntigenHistocompatibility Antigens Class IProgrammed Cell Death 1 ReceptorReceptors, KIR

Autor:innen und Institutionen

  • Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. k.j.malmberg@medisin.uio.no.
  • The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. k.j.malmberg@medisin.uio.no.
  • Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. k.j.malmberg@medisin.uio.no.
  • Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
  • The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Förderung

  • Vetenskapsrådet
  • Kreftforeningen
  • Cancerfonden
  • Helse Sør-Øst RHF
  • Barncancerfonden

Zitieren

APA

Malmberg, K. J., Sohlberg, E., Goodridge, J. P., & Ljunggren, H. G. (2017). Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell “missing self” recognition. Immunogenetics, 69(8-9), 547-556. https://doi.org/10.1007/s00251-017-1011-9

Vancouver

Malmberg KJ, Sohlberg E, Goodridge JP, Ljunggren HG. Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell “missing self” recognition. Immunogenetics. 2017;69(8-9):547-556. doi:10.1007/s00251-017-1011-9

BibTeX
@article{Malmberg2017,
  author = {Malmberg, Karl-Johan and Sohlberg, Ebba and Goodridge, Jodie P and Ljunggren, Hans-Gustaf},
  title = {Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell “missing self” recognition},
  journal = {Immunogenetics},
  year = {2017},
  volume = {69},
  number = {8-9},
  pages = {547--556},
  doi = {10.1007/s00251-017-1011-9}
}
Kostenlos starten →